Pralidoxime in treatment of organophorus poisoning.
S R
SR
Mehta
S
S
Kiran
D000293:Adolescent; D000328:Adult; D000931:Antidotes / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers; D002091:Butyrylcholinesterase / Q000032:analysis*; D018849:Controlled Clinical Trials as Topic; D005260:Female; D006801:Humans; D007194:India; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D062025:Organophosphate Poisoning; D011041:Poisoning / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011220:Pralidoxime Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000931:Antidotes; D015415:Biomarkers; D011220:Pralidoxime Compounds; D002091:Butyrylcholinesterase; C028797:pralidoxime